Short sellers move out of these 3 biotechs

Amgen, Celgene and Pharmacyclics see short interest drop recently.

By Benzinga Apr 11, 2013 10:16AM

Pills CorbisBy Nelson Hem

The short interest in biotech and emerging pharmaceutical companies was mixed in the final two weeks of March.

The number of shares sold short in Alexion Pharmaceuticals (ALXN), Arena Pharmaceuticals (ARNA), Illumina (ILMN), Onyx Pharmaceuticals (ONXX), Vertex Pharmaceuticals (VRTX) and VIVUS (VVUS) grew somewhat between the February 28 and March 15 settlement dates.

But short interest in Amgen (AMGN), Celgene (CELG) and Pharmacyclics (PCYC) declined in that period. We take a closer look at them below.

Short sellers also shied away from Biogen Idec (BIIB), Dendreon (DNDN), Gilead Sciences (GILD) and Regeneron Pharmaceuticals (REGN) during that time.


This California-based biotechnology medicines company saw short interest fall almost 15% to 10.24 million shares, on top of a 19% drop in the previous period. The end-of-March figure was the lowest number of shares sold short in at least a year and about 1.4% of the float.

The company develops and markets human therapeutics based on advances in cellular and molecular biology for grievous illnesses. It said during the period that a melanoma drug showed promise in key Phase 3 trial. Amgen has a market capitalization of more than $79 billion and a dividend yield near 1.8%. Its return on equity is almost 23%.

Only 12 of the 27 analysts surveyed by Thomson/First Call recommend buying shares, but just one recommends selling. The current share price is higher than the mean price target, which means the analysts do not see any upside potential at this time.

The share price is up about 17% year-to-date and reached a multiyear high last week. Over the past six months, the stock has outperformed competitor Teva Pharmaceutical (TEVA) and the S&P 500.


The short interest in this biopharmaceutical company declined by about 23% in the period to 4.95 million. That erased a 16% increase in short interest in the previous period. The number of shares sold short represented a little more than 1% of the total float at the end of March.

This maker of therapies to treat cancer and immune-inflammatory related diseases has a market cap of more than $47 billion. Celgene is an S&P 500 component, and in late March it was a Jim Cramer pick despite at least one analyst downgrade. The company's long-term earnings per share growth forecast is about 23%, and the return on equity is about 26%.

Out of the 29 analysts polled, 13 rate the stock at "strong buy" and 10 others also recommend buying shares. However, the share price has outrun the mean price target. For what it is worth, the street-high price target suggests more than 16% upside.

Shares are up more than 43% year-to-date and reached a multiyear high last week. Celgene has outperformed competitor Johnson & Johnson (JNJ) and the S&P 500 over the past six months.


Short interest in this clinical-stage biopharmaceutical company dropped more than 19% to 2.77 million shares. That is the smallest number of shares sold short in the past year, and days to cover has fallen to less than three. Short interest is almost 5% of the company's float.

This Sunnyvale, California-based company focuses on the development and commercialization of small-molecule drugs for the treatment of cancer and immune mediated diseases. Pharmacyclics has a market cap of more than $5 billion. The return on equity is more than 42% and the operating margin is better than the industry average. But the price-to-earnings ratio is higher than the industry average.

Seven of the 13 polled analysts recommend buying shares, though none recommend selling. Their mean price target represents about 22% potential upside, relative to the current share price. That target would be a new multiyear high.

Shares are now trading more than 22% higher year-to-date, despite pulling back more than 18% in the past month. Over the past six months, the stock has outperformed larger competitor Merck (MRK) and the broader markets.

More from Benzinga



Copyright © 2014 Microsoft. All rights reserved.

Fundamental company data and historical chart data provided by Morningstar Inc. Real-time index quotes and delayed quotes supplied by Morningstar Inc. Quotes delayed by up to 15 minutes, except where indicated otherwise. Fund summary, fund performance and dividend data provided by Morningstar Inc. Analyst recommendations provided by Zacks Investment Research. StockScouter data provided by Verus Analytics. IPO data provided by Hoover's Inc. Index membership data provided by Morningstar Inc.


StockScouter rates stocks from 1 to 10, with 10 being the best, using a system of advanced mathematics to determine a stock's expected risk and return. Ratings are displayed on a bell curve, meaning there will be fewer ratings of 1 and 10 and far more of 4 through 7.

120 rated 1
268 rated 2
439 rated 3
709 rated 4
641 rated 5
609 rated 6
640 rated 7
516 rated 8
272 rated 9
152 rated 10

Top Picks

TAT&T Inc9



Top Stocks provides analysis about the most noteworthy stocks in the market each day, combining some of the best content from around the MSN Money site and the rest of the Web.

Contributors include professional investors and journalists affiliated with MSN Money.

Follow us on Twitter @topstocksmsn.